Moderna and Merck's Cancer Vaccine Hits Big in Melanoma Trial

Moderna and Merck just hit a home run with their personalized mRNA cancer vaccine! In a late-stage trial, it showed promise in keeping melanoma from returning in high-risk patients. By teaming up with Merck's Keytruda, they supercharged survival rates! And guess what? They're not stopping at melanoma—more trials for other cancers are on the horizon!